Paul P. Yeung, MD, MPH, affiliated with Bristol Myers Squibb in Princeton, New Jersey, has published extensively on the treatment of major depressive disorder and schizophrenia/schizoaffective disorders. His work includes clinical trials evaluating pharmacologic interventions such as xanomeline with trospium chloride for agitation in schizophrenia and cariprazine and desvenlafaxine succinate for major depressive disorder. Yeung’s research spans randomized, double-blind, placebo-controlled studies published between 2007 and 2025.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
